Detection of Bacterial DNA and Collagen Metabolism in Acutely Ruptured Achilles Tendons

July 28, 2021 updated by: Allan Cramer, Copenhagen University Hospital, Hvidovre

The etiology and pathogenesis of acute Achilles tendon ruptures are complex and not fully understood. It is well known that they are associated with pre-existing pathological alterations, similar to the changes observed in tendinopathy.

The present study investigates if bacteria and collagen metabolism play a role in the etiology of acute Achilles tendon rupture. During surgery, 20 patients will have taken two biopsies from the ruptured part of the tendon and two biopsies from the healthy tissue of the same tendon 2-4 cm proximal to the rupture, as a control.

Study Overview

Status

Completed

Detailed Description

Objectives

  1. To investigate the collagen turnover in Achilles tendons prior to a rupture.
  2. To investigate the relative collagen turnover in Achilles tendons the days immediately after a rupture.
  3. To investigate the acute collagen protein synthesis rate in acutely ruptured Achilles tendons.
  4. To investigate if bacterial DNA is present in samples from the degenerative tissue in acutely ruptured Achilles tendons compared with samples from the healthy tissue of the ruptured tendon.

Background

Tendon ruptures are severe injuries that potentially lead to reduced function, reduced activity and sick leave. In younger, sports active individuals with strong tendons, an acute traumatic event is usually needed to trigger a rupture. With age the tendons are exposed to degenerative changes and can therefore rupture in everyday activities (spontaneously).

The etiology and pathogenesis of spontaneous tendon ruptures are complex and not fully understood. It is well known that they are associated with pre-existing pathological alterations, similar to the changes ob-served in tendinopathy. Recently, Dakin et al. found that ruptured Achilles tendons show evidence of chronic (non-resolving) inflammation. The condition might be a result of collagenolytic injury followed by failed tendon healing. Yet, other theories are still highly debated.

Many predisposing factors have been proposed to contribute to the pathological alterations of tendons. Studies found that factors such as increasing age, dominant arm, history of trauma and specific acromial anatomy are associated with rotator cuff tear. It is suggested that spontaneous tendon ruptures, primary Achilles tendon, are related to systemic and injectable steroids, fluoroquinolone use and some rheumatic diseases. Furthermore, studies have shown possible associations between genetic factors and tendon injury. The mentioned factors may influence the initiation and development of the patho-logical alterations that weaken the tendons. However, it is certain there are other mechanisms and predis-posing factors that need to be investigated.

Heinemeier et al. found that the bulk of the collagen matrix of healthy human Achilles tendon core is an essentially permanent structure that is laid down during height growth and has limited turnover in adults. The findings were based on the 14C bomb pulse method, and unpublished data from the same re-search group (using this method) indicates that an abnormally high rate of collagen turnover precedes symptoms of tendon overuse (tendinopathy)It is of great interest to investigate if increased collagen turno-ver predisposes to tendon rupture.

Recently, Rolf et al. demonstrated the presence of bacterial DNA in 25% of samples from ruptured Achilles tendons. Polymerase chain reaction (PCR) was used to identify the highly conserved bacterial 16S rDNA gene in the tendons. This finding open the question, if bacterial depositions play a role in the etiology of spontaneous tendon ruptures In order to prevent tendon ruptures it is essential to improve our understanding of the etiology. A better understanding may also lead to development of new therapeutic options.

In this cross-sectional study, we aim to investigate if bacteria potentially are contributing to the etiology of acute Achilles tendon rupture, Additionally, we also investigate if tendon ruptures are preceded by an in-creased collagen turnover.

Design of the study

The study is conducted as a cross-sectional study. Patients with acute rupture of the Achilles tendon are included The study aims to include 20 patients with acute Achilles tendon rupture.

The procedure for the patient:

  1. At the day of inclusion, the patients will have taken a blood sample and ingest 150ml of deuterium oxide (D2O).
  2. At the day of the surgery, the patient will meet 3 hours before the beginning of the surgery. A bolus of stable isotope (15N marked proline tracer) will be injected and afterwards continuous infused trough the antecubital vein. Blood samples are taken before infusion starts, 30min after, 60min af-ter, 120min after and when the biopsies are taken.
  3. During the surgery, the patients will have taken:

    1. Two biopsies from the stump end of the ruptured tendon or ligament.
    2. Two control biopsies 2-4 cm proximal to the stump end of the ruptured Achilles tendon.

Procedure for biopsies

All biopsies are taken by trained orthopedic surgeons. Every biopsy is taken during surgery in an operating theatre. Before the beginning of the surgery a sterile table is prepared containing three packs of sterile scalpels and forceps, and 8 containers for biopsies with the patient's social security (CPR), the type of analysis and a continues number individually describing each biopsy.

The 8 containers will hold:

  1. Biopsy from the stump end of the ruptured tendon for 16S rDNA analysis.
  2. Biopsy from the stump end of the ruptured tendon for 14C bomb pulse method
  3. Biopsy from the stump end of the ruptured tendon for isotope analysis (deuterium oxide and 15N marked proline).
  4. Biopsy from the stump end of the ruptured tendon for mRNA analysis.
  5. Biopsy from the ruptured tendon 2-4 cm proximal to the stump end for 16S rDNA analysis.
  6. Biopsy from the ruptured tendon 2-4 cm proximal to the stump end for 14C bomb pulse.
  7. Biopsy from the ruptured tendon 2-4 cm proximal to the stump end for isotope analysis (deuterium oxide and 15N marked proline).
  8. Biopsy from the ruptured tendon 2-4 cm proximal to the stump end for mRNA analysis

Biopsies from ruptured tendons

Achilles tendon:

The biopsies are taken during open surgery. To prevent contamination of the biopsies the following proce-dure is followed:

  1. Surgical rub and draping according to normal guidelines.
  2. Skin incision and dissection according to normal guidelines.
  3. As the ruptured tendon is identified, a new pack containing a sterile scalpel and a forceps is opened. The instruments are only used for taking the biopsy and does not get in contact with the surrounding tissue.
  4. 2 biopsies, 10mm long, 1mm broad and 1mm deep, are taken from the degenerated tendon tissue at the rupture site.
  5. The first biopsy is placed in a container (for bacterial detection). On a sterile board, the second bi-opsy is divided in three and placed in three different containers (one for 14C bomb pulse, one for isotope analysis (both deuterium oxide and 15N marked proline) and one for mRNA). These contain-ers are frozen down to -80oC.
  6. A second new pack containing a sterile scalpel and a forceps is opened and 2 biopsies 10 mm long, 1mm broad and 1 mm deep are taken 2-4 cm proximal to the rupture site.
  7. The first biopsy is placed in a container (for bacterial detection) On a sterile board, the second biopsy is divided in three and placed in three different containers (one for 14C bomb pulse, one for isotope analysis (both deuterium oxide and 15N marked proline) and one for mRNA). These contain-ers are frozen down to -80oC.

Contamination tests

PCR and sequencing - Both a negative and a positive control is included in the test. Numbers of cycles in positive samples will also be included in the interpretation. Exclusively environmental bacterial species never been related to human disease are likely to be regarded as contaminants.

Blood culture - During surgery, blood a sample is send for culture to investigate if bacteria were presented in the blood.

Bacterial cultures - Bacterial culture tests are conducted on all patients. The investigated samples are taken with swaps from:

  • Patients skin area over the surgical site.
  • The blade of the used scalpel.

The swaps are collected in separate glass tubes and send to Department of Microbiology, Hvidovre Hospi-tal. The swaps are tested on multiple culture media for multiple species.

Blinding of the analysis

For each included patient, the 2 containers with biopsies for bacterial detection will get a randomized continues number. These numbers can, via a key document (paper form), reveal if the biopsy has been taken from the degenerative tissue or from the healthy tissue. The person responsible for the analyze of the bacterial DNA has no access to the key document.

Data registration during inclusion

  • Patient ID
  • Social security number
  • Phone number
  • Age
  • Weight
  • Date of examination
  • Date and time of insult
  • Corticosteroid injection (number and time)
  • History of infection

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hvidovre, Denmark, 2650
        • Department of Orthopedic Surgery, Copenhagen University Hospital, Hvidovre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients diagnosed with acute Achilles tendon rupture, seen in the outpatient clinic at Copenhagen University Hospital, Hvidovre.

Description

Inclusion Criteria:

  • Age 18-70 years
  • Appointment in the Outpatients Department within 4 days after injury.
  • Total Acute Achilles tendon rupture
  • The patient must be able to speak and understand Danish.
  • The patient must be able to give informed consent.

Exclusion Criteria:

  • Rupture of the Achilles tendon either at the insertion on the calcaneus or at musculotendinous junction of the triceps surae.
  • Previous rupture of the same Achilles tendon
  • Undergone any surgery in the same region as the affected Achilles tendon.
  • In medical treatment of diabetes.
  • Present infection in the affected region.
  • Contra-indication for surgery: severe arthrosclerosis with no palpable pulse in the foot, broken skin in the Achilles region of the injured leg.
  • Inability to lie in prone position on the operating table.
  • Rheumatoid arthritis or any other inflammatory disorder of the joints.
  • Terminal illness or severe medical illness. ASA score higher than or equal to 3.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Operatively treated patients with Achilles tendon rupture
Cohort of operatively treated patients with acute Achilles tendon rupture.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
14C concentration in acutely ruptured Achilles tendons
Time Frame: The outcome measure will be assesed at time of surgery
14C concentration in biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture are compared to the known historical values of atmospheric 14C to estimate the rate of collagen turnover. The values for turnover in the biopsies will be compared to the known rates of turnover in healthy tendons.
The outcome measure will be assesed at time of surgery
Heavy water (D2O) enrichment in acutely ruptured Achilles tendons
Time Frame: The outcome measure will be assesed at time of surgery
2H isotope enrichment in the biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture.
The outcome measure will be assesed at time of surgery
Fractional synthesis rate of protein at time of surgery in acutely ruptured Achilles tendons.
Time Frame: The outcome measure will be assesed at time of surgery
The enrichment of the 15N marked proline tracer measured in the biopsies from the ruptured part of the tendons and in the control biopsies and compared to the enrichment of 15N marked proline in the blood. Based on that, the fractional synthesis rate of protein at the time of surgery is calculated.
The outcome measure will be assesed at time of surgery
Presence of bacteria in acutely ruptured Achilles tendons.
Time Frame: The outcome measure will be assesed at time of surgery
Presence of bacterial DNA in the biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture detected by 16s rDNA PCR
The outcome measure will be assesed at time of surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Chair: Kristoffer W Barfod, MD, Copenhagen University Hospital, Hvidovre

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 3, 2019

Primary Completion (Actual)

April 1, 2021

Study Completion (Actual)

April 1, 2021

Study Registration Dates

First Submitted

April 15, 2019

First Submitted That Met QC Criteria

April 25, 2019

First Posted (Actual)

April 30, 2019

Study Record Updates

Last Update Posted (Actual)

July 29, 2021

Last Update Submitted That Met QC Criteria

July 28, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H-18010363

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Achilles Tendon Rupture

3
Subscribe